Introduction
Macular oedema is the most common cause of visual impairment in diabetic patients. The exact pathogenesis of diabetic macular oedema (DME) has not been elucidated, although a breakdown of the inner blood-retinal barrier seems to be a reasonable explanation. The important pathophysiology of DME is the loss of retinal capillary pericytes, resulting in increased vascular permeability. [1] [2] [3] [4] [5] [6] The 3-year risk of moderate visual loss due to macular oedema was 32% in the Early Treatment Diabetic Retinopathy Study (ETDRS). Focal macular laser photocoagulation has been shown to be effective in the treatment of DME in a large prospective multicenter randomized clinical trial of ETDRS. 7 However, some treated eyes may be resistant to laser photocoagulation or efficient laser treatment could not be performed due to diffuse macular oedema. Therefore, the failure of laser photocoagulation in these eyes has prompted interest in other treatment modalities, such as intravitreal triamcinolone acetonide (IVTA) injection, 4, 5, 8, 9 pars plana vitrectomy, 10, 11 or treatment with protein kinase C inhibitors. 12 Retinal hypoxia is the primary cause of diabetic retinopathy, which increases expression of vascular endothelial growth factor (VEGF). As known, VEGF is a potent inducer of vascular permeability that has been shown to cause leakage from retinal vessels and contribute to DME. 13 Bevacizumab (Avastin, Genentech Inc., South San Francisco, CA, USA), a full length, humanized monoclonal antibody against VEGF, also binds and inhibits all the biologically active forms of VEGF, and approved by the Food and Drug Administration for the treatment of metastatic colorectal cancer. 14, 15 Bevacizumab has been used for intravitreal injection in patients with choroidal neovascularization, iris neovascularization, vitreous haemorrhage, and macular oedema, and shown to provide beneficial effects in such patients. [16] [17] [18] [19] [20] However, there is only one study showing the beneficial effect of intravitreal bevacizumab therapy for persistent diffuse DME. 20 Therefore, this study investigated the efficacy of intravitreal bevacizumab for primary treatment of DME by using Heidelberg retinal tomograph II (HRT II).
Patients and methods
A total of 30 eyes of 30 diabetic patients who underwent intravitreal bevacizumab injection as the primary treatment for DME were included in this study. There were 13 women and 17 men, and the mean age of the patients was 56.1±8.5 years (range, 40-73 years). All patients had macular oedema with hyperfluorescent leakage on fundus fluorescein angiography. The mean duration of DME was 7.4±3.9 months (range, 3-16 months). A detailed history of medication was obtained, and the patients were excluded from the study if they had uncontrolled systemic hypertension, thromboembolic events, severe renal dysfunction, nephrotic syndrome, and dysproteinemias or receiving vasoactive drugs or antioxidant.
Before intravitreal bevacizumab injection, some eyes had received peripheral scatter laser photocoagulation to ablate ischaemic areas or neovascularization, but no eyes received any treatment for DME. Intravitreal injection of bevacizumab (2.5 mg/0.1 ml) was offered as the first treatment of DME. All patients were fully informed about the experimental character of the treatment and informed consent was obtained from each patient. The study followed the tenets of Declaration of Helsinki. Baseline parameters were documented including bestcorrected visual acuity (BCVA), oedema map values of HRT II, fundus fluorescein angiography (FFA) findings, and IOP. BCVA for each eye was ascertained using Snellen chart, which was situated 20 ft (approximately 6 m) away from the patient before intravitreal applications, and then all eyes were tested with the same correction throughout the follow-up period. The proper average VA was computed by converting the value to the LogMAR equivalent, and taking the average of the LogMAR values as described by Holladay. 21 Statistical calculations were performed using LogMAR values for VA. All intravitreal injections were performed by the same surgeon (AO) under topical anaesthesia. The drug was drawn under sterile conditions from a bevacizumab infusion bottle. The lid was prepared with povidoneiodine 5% applied directly to the eye, and bevacizumab was injected into the anterior vitreous 3.5 mm posterior to the limbus in pseudophakic eyes and 4.0 mm posterior to the limbus in phakic eyes with a tuberculin syringe and 27-gauge needle. A cotton-tipped applicator was applied at the injection site immediately after the removal of the needle to prevent reflux. Indirect ophthalmoscopy was used to confirm the central retinal artery perfusion. Topical ciprofloxacin drops were applied four times daily for 1 week.
The eyes were examined after 1 week and every 4 weeks. Response to the treatment was monitored by VA assessment, FFA, and HRT II. Potential drug-or injection-related complications were also recorded, if present. Patients received reinjections when there was a recurrence of DME, and the recurrence was considered when there was a decrease in BCVA associated with an increase of intraretinal fluid due to macular oedema on FFA and/or HRT II.
The analysis of macular oedema was performed using the HRT II Macular oedema module. Oedema map value of HRT II was used to evaluate the changes at the macula after bevacizumab injection. The HRT II is a confocal laser scanning system that requires a series of optical section images at different locations of the focal plane. Technical details of the instrument have been described elsewhere. 22 The patient's macula was focused on the monitor screen by adjusting the location of the focal plane, the best focus being directly related to subject's refractive error. The 670-nm wavelength diode laser was used to image the macula using a 151 by 151 field of view. The total scan depth was adjusted according to the thickness of the structure to be analysed from 0.50 to 4.00 mm.
Statistical analysis
Results are presented as means±SD. Statistical evaluation of the data was performed with two-way ANOVA. The difference was considered statistically significant when P-value was lower than 0.05.
Results
All patients had clinically significant macular oedema according to the ETDRS classification at the baseline examination and completed 12 weeks of follow-up. Eighteen patients (60%) had PDR, and all these patients had had prior scatter photocoagulation at least 6 months before injection. Seventeen cases received a second (56.6%) intravitreal injection of bevacizumab, and two (6.6%) needed a third injection. The mean VAs, oedema map values, and intraocular pressures (IOPs) of the patients before and after intravitreal bevacizumab injection are presented in Table 1 . There were statistically significant differences in VA after bevacizumab injection when compared with pretreatment values (for each, Po0.001). After a mean follow-up period of 5.6 months, VA increased in 24 of 30 eyes with a mean of 2.4 ± 1.6, 2.7 ± 1.9 and 2.8 ± 2.0 Snellen lines at the 1-, 3-month, and last visit follow-up intervals, respectively. VA remained unchanged in five eyes, and decreased in one eye and showed increased fluorescein leakage on FFA.
Twenty-seven eyes showed a reduction in macular oedema map value after intravitreal bevacizumab injection. Mean oedema map value decreased from a baseline value of 2.4 ± 0.6 to a value of 1.6 ± 0.4 at the last visit control examinations. Mean reduction of oedema map values at 1-, 3-month, and last visit was 29.1, 29.1,and 33.3%, respectively and the differences were statistically significant when compared with preinjection values (for each, Po0.001).
Average IOP values at 1-, 3-month, and last visit were not statistically significant when compared with preinjection values. Mild anterior chamber cellular reaction was observed in four eyes (13.3%), but the inflammation resolved within a week with topical corticosteroid. No other injection-or drug-related complications were observed. Discussion DME is the most important cause of VA impairment in patients with diabetes mellitus and may be localized or diffused. The prognosis of diffused macular oedema is poorer when compared with focal oedema. Although the exact pathophysiologic mechanism responsible for DME remain uncertain, the disruption of the inner bloodretinal barrier is known to be associated with metabolic alterations affecting the retinal epithelium or retinal vascular endothelium. [1] [2] [3] [4] The ETDRS 7 demonstrated the beneficial effect of laser photocoagulation on preventing visual loss in eyes with diffuse DME. However, macular oedema may persist in some eyes despite laser treatment. IVTA injection appears to be a promising treatment for DME, the treatment is not without risks, and complications can be attributed to the injection procedure or to the corticosteroid suspension. Reported injection-related complications include endophthalmitis, lens injuries, vitreous haemorrhage, and retinal detachment. 23, 24 Corticosteroid-associated adverse events include IOP elevation, cataract progression, pseudoendophthalmitis, and pseudohypopyon. Moreover, the efficacy of IVTA is transient and repeated injections are required.
VEGF plays an important role in breakdown of the blood-retina barrier with increased vascular permeability resulting in retinal oedema. Therefore, anti-VEGF therapy may be a promising treatment option for ocular neovascularization and DME. Intravitreal injection of pegaptanib (anti-VEGF aptamer) has recently demonstrated promising results for DME. Cunningham et al 25 reported that patients who had underwent intravitreal injection of pegaptanib had better VA outcomes with reduction in central retinal thickness and less additional therapy with laser photocoagulation. More recently, intravitreal bevacizumab has been used to reduce the breakdown of the inner blood-retinal barrier, extravasation from leaking blood vessels, and inhibition of neovascularization. They inhibit the release of VEGF, contribute to the integrity of the inner blood-retinal barrier, reduce extravasation from leaking blood vessels, and have beneficial effect in the prevention and treatment of macular oedema. 20, 26, 27 The safety of intravitreal bevacizumab has been confirmed by previous animal studies and human trials, 28, 29 and intravitreal injection of bevacizumab has recently been reported to be effective in macular oedema of various etiologies. 20, [30] [31] [32] [33] Results of our study suggest that intravitreal bevacizumab injection appears to be effective in the primary treatment of DME. In our study, 24 eyes showed an improvement in VA with a decrease in fluorescein leakage on FFA (Figure 1a and b) . Oedema map values of HRT II showed a reduction in 27 eyes (Figure 2a and b) . The results of our study confirm previous reports showing the beneficial effect of intravitreal bevacizumab in the treatment of DME. In a recent study with an intravitreal injection of 1.25 mg bevacizumab, Haritoglou et al 20 reported an improvement in VA from a baseline value of 0.86 logMAR to a value of 0.75 logMAR after 6 weeks of injection in patients with DME who did not respond to other treatments such as photocoagulation, IVTA injection, or vitrectomy. An increase in VA of at least three lines was observed in 15 of 51 eyes at a 6-week follow-up, and in 6 of 23 eyes completing 12 weeks of follow-up. Mean reduction in central macular thickness was 16.9% at 6 weeks, 24.75% at 12 weeks after the injection. In this study, VA increased with a mean of 2.4, 2.7, and 2.8 Snellen lines at 1-, 3-month, and last visit follow-up intervals, respectively. This high success in our Bevacizumab in diabetic macular oedema A Ö zkiris6 study may be explained by performing intravitreal bevacizumab injection as the primary treatment of DME or a short duration of DME in our patients or using of 2.5 mg of bevacizumab. After intravitreal bevacizumab injection, complications such as anterior chamber inflammation, endophthalmitis, vitreous haemorrhage, subconjunctival haemorrhage, and retinal detachment may occur. In our study, four eyes developed mild anterior segment inflammation, which completely resolved in a week after topical application of corticosteroids. No other complications were observed during the follow-up period.
This study has some differences from previous studies. First, the dosage of bevacizumab injected as the primary treatment of macular oedema. Haritoglou et al 20 used 1.25 mg bevacizumab in the treatment of DME. Second, macular oedema was evaluated by HRT II before and after bevacizumab injection, and reduction in oedema map values was demonstrated as the effectiveness of bevacizumab application. This study has several limitations. First, the follow-up time was relatively short, but visual and anatomical responses were apparent during the follow-up time. Second, there is no control group in this study, but it can be argued that the enrolled eyes serve as their own controls because the pre-and posttreatment VAs and oedema map values of the same patients were compared. Third, VA was measured on a Snellen chart, as opposed to the more standardized and accepted ETDRS chart. However, all eyes were tested with the same correction throughout the follow-up period.
In conclusion, this study demonstrated that intravitreal bevacizumab application is an effective approach with promising results for the primary treatment of DME. Intravitreal bevacizumab provides significant resolution of macular oedema and improvement in VA. However, further studies are needed to obtain the long-term results of such application.
